LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Search

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

29.38 8.13

Visão Geral

Variação de preço das ações

24h

Atual

Mín

29.33

Máximo

29.89

Indicadores-chave

By Trading Economics

Rendimento

23M

7.4M

Vendas

18M

99M

EPS

0.06

Margem de lucro

7.468

Funcionários

342

EBITDA

23M

11M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

-2.78% downside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

794M

3.2B

Abertura anterior

21.25

Fecho anterior

29.38

Sentimento de Notícias

By Acuity

36%

64%

91 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de nov. de 2025, 10:30 UTC

Ganhos

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

22 de nov. de 2025, 10:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

22 de nov. de 2025, 09:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

21 de nov. de 2025, 22:42 UTC

Conversa de Mercado

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21 de nov. de 2025, 21:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

21 de nov. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

21 de nov. de 2025, 21:47 UTC

Conversa de Mercado

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21 de nov. de 2025, 21:43 UTC

Conversa de Mercado

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21 de nov. de 2025, 20:18 UTC

Conversa de Mercado

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21 de nov. de 2025, 20:14 UTC

Conversa de Mercado

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21 de nov. de 2025, 19:48 UTC

Conversa de Mercado

Precious Metals Fall for the Week -- Market Talk

21 de nov. de 2025, 19:44 UTC

Ganhos

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21 de nov. de 2025, 19:37 UTC

Conversa de Mercado

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21 de nov. de 2025, 19:27 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

21 de nov. de 2025, 19:27 UTC

Conversa de Mercado
Ganhos

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21 de nov. de 2025, 19:20 UTC

Conversa de Mercado

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21 de nov. de 2025, 18:44 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21 de nov. de 2025, 18:37 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21 de nov. de 2025, 18:34 UTC

Conversa de Mercado
Ganhos

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21 de nov. de 2025, 18:28 UTC

Ganhos

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 de nov. de 2025, 18:03 UTC

Conversa de Mercado

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21 de nov. de 2025, 17:24 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

21 de nov. de 2025, 17:24 UTC

Conversa de Mercado

Intuit Seen on Path to Increase Growth -- Market Talk

21 de nov. de 2025, 17:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

21 de nov. de 2025, 17:05 UTC

Conversa de Mercado

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21 de nov. de 2025, 16:56 UTC

Conversa de Mercado

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21 de nov. de 2025, 16:47 UTC

Conversa de Mercado

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21 de nov. de 2025, 16:35 UTC

Aquisições, Fusões, Aquisições de Empresas

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21 de nov. de 2025, 16:09 UTC

Ganhos

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21 de nov. de 2025, 15:59 UTC

Conversa de Mercado

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

-2.78% parte inferior

Previsão para 12 meses

Média 28.67 USD  -2.78%

Máximo 32 USD

Mínimo 21 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

5

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

12.42 / 14.93Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

91 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat